The trial is a phase 1/2 study for Vertex’s VX-880, an insulin-producing therapy being tested among diabetes patients with hypoglycemia, according to a Jan. 7 news release. Seventeen participants were enrolled in the study, according to clinicaltrials.gov, but one patient withdrew consent from the study, the release said.
All 14 patients who received VX-880 “demonstrated islet cell engraftment and production of endogenous insulin,” Vertex said.
“Two patient deaths, both unrelated to VX-880, have occurred,” the drugmaker said. “Vertex has placed the study on a protocol-specified pause, pending review of the totality of the data by the independent data monitoring committee and global regulators.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.